140 related articles for article (PubMed ID: 36403799)
1. Human skeletal dysplasia causing L596P-mutant alters the conserved amino acid pattern at the lipid-water-Interface of TRPV4.
Das R; Mohanta S; Dubey NK; Das NK; Goswami C
Biochim Biophys Acta Biomembr; 2023 Feb; 1865(2):184085. PubMed ID: 36403799
[TBL] [Abstract][Full Text] [Related]
2. TRPV4-pathy, a novel channelopathy affecting diverse systems.
Dai J; Cho TJ; Unger S; Lausch E; Nishimura G; Kim OH; Superti-Furga A; Ikegawa S
J Hum Genet; 2010 Jul; 55(7):400-2. PubMed ID: 20505684
[TBL] [Abstract][Full Text] [Related]
3. Ratio of Hydrophobic-Hydrophilic and Positive-Negative Residues at Lipid-Water-Interface Influences Surface Expression and Channel Gating of TRPV1.
Saha S; Mohanta S; Das R; Dalai R; Divyanshi ; Tiwari N; Tiwari A; Kumar A; Goswami C
J Membr Biol; 2022 Jun; 255(2-3):319-339. PubMed ID: 35608627
[TBL] [Abstract][Full Text] [Related]
4. TRPV4 expresses in bone cell lineages and TRPV4-R616Q mutant causing Brachyolmia in human reveals "loss-of-interaction" with cholesterol.
Das R; Goswami C
Biochem Biophys Res Commun; 2019 Oct; 517(4):566-574. PubMed ID: 31387748
[TBL] [Abstract][Full Text] [Related]
5. L596-W733 bond between the start of the S4-S5 linker and the TRP box stabilizes the closed state of TRPV4 channel.
Teng J; Loukin SH; Anishkin A; Kung C
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3386-91. PubMed ID: 25737550
[TBL] [Abstract][Full Text] [Related]
6. TRPV4-associated skeletal dysplasias.
Nishimura G; Lausch E; Savarirayan R; Shiba M; Spranger J; Zabel B; Ikegawa S; Superti-Furga A; Unger S
Am J Med Genet C Semin Med Genet; 2012 Aug; 160C(3):190-204. PubMed ID: 22791502
[TBL] [Abstract][Full Text] [Related]
7. The puzzle of TRPV4 channelopathies.
Nilius B; Voets T
EMBO Rep; 2013 Feb; 14(2):152-63. PubMed ID: 23306656
[TBL] [Abstract][Full Text] [Related]
8. Follistatin in chondrocytes: the link between TRPV4 channelopathies and skeletal malformations.
Leddy HA; McNulty AL; Lee SH; Rothfusz NE; Gloss B; Kirby ML; Hutson MR; Cohn DH; Guilak F; Liedtke W
FASEB J; 2014 Jun; 28(6):2525-37. PubMed ID: 24577120
[TBL] [Abstract][Full Text] [Related]
9. TRPV4-mediated channelopathies.
Verma P; Kumar A; Goswami C
Channels (Austin); 2010; 4(4):319-28. PubMed ID: 20676052
[TBL] [Abstract][Full Text] [Related]
10. Influence of membrane cholesterol in the molecular evolution and functional regulation of TRPV4.
Kumari S; Kumar A; Sardar P; Yadav M; Majhi RK; Kumar A; Goswami C
Biochem Biophys Res Commun; 2015 Jan; 456(1):312-9. PubMed ID: 25434996
[TBL] [Abstract][Full Text] [Related]
11. Preferential selection of Arginine at the lipid-water-interface of TRPV1 during vertebrate evolution correlates with its snorkeling behaviour and cholesterol interaction.
Saha S; Ghosh A; Tiwari N; Kumar A; Kumar A; Goswami C
Sci Rep; 2017 Dec; 7(1):16808. PubMed ID: 29196683
[TBL] [Abstract][Full Text] [Related]
12. Progesterone interacts with the mutational hot-spot of TRPV4 and acts as a ligand relevant for fast Ca
Dubey NK; Mishra S; Goswami C
Biochim Biophys Acta Biomembr; 2023 Aug; 1865(6):184178. PubMed ID: 37225030
[TBL] [Abstract][Full Text] [Related]
13. The amino-terminal domain of TRPV4 channel is involved in its trafficking to the nucleus.
Méndez-Gómez S; Espadas-Álvarez H; Ramírez-Rodríguez I; Domínguez-Malfavón L; García-Villegas R
Biochem Biophys Res Commun; 2022 Feb; 592():13-17. PubMed ID: 35007845
[TBL] [Abstract][Full Text] [Related]
14. Role of TRPV4 in skeletal function and its mutant-mediated skeletal disorders.
Das R; Goswami C
Curr Top Membr; 2022; 89():221-246. PubMed ID: 36210150
[TBL] [Abstract][Full Text] [Related]
15. De novo
Ragamin A; Gomes CC; Bindels-de Heus K; Sandoval R; Bassenden AV; Dib L; Kok F; Alves J; Mathijssen I; Medici-Van den Herik E; Eveleigh R; Gayden T; Pullens B; Berghuis A; van Slegtenhorst M; Wilke M; Jabado N; Mancini GMS; Gomez RS
J Med Genet; 2022 Mar; 59(3):305-312. PubMed ID: 33685999
[TBL] [Abstract][Full Text] [Related]
16. TRPV4 related skeletal dysplasias: a phenotypic spectrum highlighted byclinical, radiographic, and molecular studies in 21 new families.
Andreucci E; Aftimos S; Alcausin M; Haan E; Hunter W; Kannu P; Kerr B; McGillivray G; McKinlay Gardner RJ; Patricelli MG; Sillence D; Thompson E; Zacharin M; Zankl A; Lamandé SR; Savarirayan R
Orphanet J Rare Dis; 2011 Jun; 6():37. PubMed ID: 21658220
[TBL] [Abstract][Full Text] [Related]
17. Mice expressing mutant Trpv4 recapitulate the human TRPV4 disorders.
Weinstein MM; Tompson SW; Chen Y; Lee B; Cohn DH
J Bone Miner Res; 2014 Aug; 29(8):1815-1822. PubMed ID: 24644033
[TBL] [Abstract][Full Text] [Related]
18. Novel and recurrent TRPV4 mutations and their association with distinct phenotypes within the TRPV4 dysplasia family.
Dai J; Kim OH; Cho TJ; Schmidt-Rimpler M; Tonoki H; Takikawa K; Haga N; Miyoshi K; Kitoh H; Yoo WJ; Choi IH; Song HR; Jin DK; Kim HT; Kamasaki H; Bianchi P; Grigelioniene G; Nampoothiri S; Minagawa M; Miyagawa SI; Fukao T; Marcelis C; Jansweijer MC; Hennekam RC; Bedeschi F; Mustonen A; Jiang Q; Ohashi H; Furuichi T; Unger S; Zabel B; Lausch E; Superti-Furga A; Nishimura G; Ikegawa S
J Med Genet; 2010 Oct; 47(10):704-9. PubMed ID: 20577006
[TBL] [Abstract][Full Text] [Related]
19. Human skeletal dysplasia caused by a constitutive activated transient receptor potential vanilloid 4 (TRPV4) cation channel mutation.
Kang SS; Shin SH; Auh CK; Chun J
Exp Mol Med; 2012 Dec; 44(12):707-22. PubMed ID: 23143559
[TBL] [Abstract][Full Text] [Related]
20. A channelopathy mechanism revealed by direct calmodulin activation of TrpV4.
Loukin SH; Teng J; Kung C
Proc Natl Acad Sci U S A; 2015 Jul; 112(30):9400-5. PubMed ID: 26170305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
